APA (7th ed.) Citation

Macaya Douoguih, Neil Goldstein, Stephan Bart, Kerstin Luhn, Wilbert Van Duijnhoven, Carla Truyers, & Benoit Callendret. (2016). Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults. Elsevier.

Chicago Style (17th ed.) Citation

Macaya Douoguih, Neil Goldstein, Stephan Bart, Kerstin Luhn, Wilbert Van Duijnhoven, Carla Truyers, and Benoit Callendret. Safety and Immunogenicity of Heterologous Ad26.ZEBOV and MVA-BN®-Filo Prime-boost Ebola Vaccines: 6-month Follow-up of a Phase I Randomized Trial in Healthy Adults. Elsevier, 2016.

MLA (9th ed.) Citation

Macaya Douoguih, et al. Safety and Immunogenicity of Heterologous Ad26.ZEBOV and MVA-BN®-Filo Prime-boost Ebola Vaccines: 6-month Follow-up of a Phase I Randomized Trial in Healthy Adults. Elsevier, 2016.